ReviewCurrent drug targets2025
Recent Advances in Understanding the Role of PEST Sequence- Containing Proteins in Retinal Neovascularization.
Review in Current drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Recent studies have identified significant advancements in understanding the role of PEST sequence-containing proteins in retinal neovascularization. Retinal neovascularization, a critical pathological process, leads to severe visual impairment associated with conditions such as diabetic retinopathy, retinopathy of prematurity, and neovascular age-related macular degeneration. These conditions represent the leading causes of blindness worldwide. Although initially effective, current anti-VEGF treatments can lose efficacy over time and impose a burden due to frequent administrations, highlighting the need for novel therapeutic targets. PEST sequences, characterized by proline, glutamic acid, serine, and threonine enrichment, are structural motifs within proteins that target them for rapid degradation via the ubiquitin-proteasome pathway. Beyond influencing protein degradation, PEST sequences are crucial in regulating angiogenesis and inflammation, essential factors in retinal disease progression. This review focuses on the dual regulatory roles of PEST sequences in VEGFR-2 degradation and stabilization, crucial receptors in angiogenic signaling, as well as their involvement in essential signaling pathways including Notch and JAK/STAT. These findings suggest that PEST sequences could serve as promising new therapeutic targets to control pathological neovascularization and associated inflammatory responses, paving the way for more effective treatments in retinal diseases. Furthermore, advances in gene editing technologies and innovative drug delivery systems enhance the potential for the development of PEST sequence-targeted therapies, offering promising avenues for future clinical applications.
Indexed as
Identifiers
40257031What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.